UNSPSC 51171916: Rabeprazole sodium

This classification denotes a proton pump inhibitor with the molecular formula C18H21N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 32828355LL, chemically known as 1h-benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)- but generally known as rabeprazole, which bears US NIH Compound Identifier 5029. European Medicines Agency schedules Rabeprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10229MIG.

UNSPSC 51171916 Rabeprazole sodium is a Commodity code that captures pharmaceutical ingredient and finished-goods procurement by state and local agencies, though recent state and local solicitations tagged under this code show limited activity directly tied to rabeprazole itself. The recent opportunities reflect a broader pattern of state and local buy­ing across generic pharmaceuticals, drug testing reagents, and water treatment chemicals—product categories that span manufacturing inputs, finished medications, and diagnostic supplies. Issuing bodies include state pharmacy benefit programs (Texas Health and Human Services Commission), county corrections and public health departments (Collin County Community Supervision and Corrections, County of Orange Public Works), and multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). Activity reflects both routine supply procurement and exploratory market research; the Texas HHS RFI on direct-to-manufacturer prescription programs signals state interest in altering procurement pathways away from traditional pharmacy benefit manager and group purchasing organization channels.

Recent opportunities cluster in Texas, California, and the Upper Midwest. The Collin County RFP 2026-327 for offender specimen collection and drug testing services (response due July 23, 2026; estimated value $600,000; two-year term with optional renewals through five years) represents county-level demand for testing services including reagent-based immunoassay and confirmation testing. The County of Orange IFB 0803008401-RE for sodium hypochlorite and sulfuric acid (response due March 27, 2026; five-year term effective September 30, 2026) demonstrates municipal utilities procurement; the solicitation offers five percent preference for certified Orange County Local Small Businesses and eight percent for Disabled Veteran Business Enterprises. The Minnesota MMCAP RFP for generic multi-source pharmaceuticals and OTC products (response due March 26, 2026; two-year term effective July 1, 2026) spans multiple states and requires vendors to work through three authorized wholesalers with pricing weighted 75 percent in evaluation. The Texas HHS RFI on direct-to-manufacturer prescriptions (posted March 27, 2026) functions as exploratory procurement intelligence rather than a live solicitation and signals future formal RFP development. No specific opportunities targeting rabeprazole sodium by name appear in recent postings; pursue opportunities under the broader pharmaceutical and diagnostic-testing families if rabeprazole is part of a larger generic or controlled-substance product portfolio.